{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:32:48Z","timestamp":1717633968703},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,5]]},"DOI":"10.7759\/cureus.61705","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:24:03Z","timestamp":1717575843000},"source":"Crossref","is-referenced-by-count":0,"title":["Flow Cytometry-Based Detection of Minimal\/Measurable Residual Disease Predicts Survival Outcomes in Pediatrics, Adolescents, and Young Adults With T-acute Lymphoblastic Leukemia"],"prefix":"10.7759","author":[{"given":"Priyavadhana","family":"Balasubramanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranay","family":"Tanwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky070","article-title":"Prospects for minimal residual disease as a surrogate endpoint in pediatric acute lymphoblastic leukemia clinical trials","volume":"2","author":"McShane LM","year":"2018","unstructured":"McShane LM, Smith MA. Prospects for minimal residual disease as a surrogate endpoint in pediatric acute lymphoblastic leukemia clinical trials. JNCI Cancer Spectr. 2018, 2:pky070. 10.1093\/jncics\/pky070","journal-title":"JNCI Cancer Spectr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry DA","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, et al.. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017, 3:e170580. 10.1001\/jamaoncol.2017.0580","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis GJ","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, et al.. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018, 131:1275-91. 10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-725804","article-title":"Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia","volume":"129","author":"Campana D","year":"2017","unstructured":"Campana D, Pui CH. Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood. 2017, 129:1913-8. 10.1182\/blood-2016-12-725804","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.234","article-title":"Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy","volume":"31","author":"Pui CH","year":"2017","unstructured":"Pui CH, Pei D, Raimondi SC, et al.. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy. Leukemia. 2017, 31:333-9. 10.1038\/leu.2016.234","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0307-6","article-title":"Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia","volume":"33","author":"Modvig S","year":"2019","unstructured":"Modvig S, Madsen HO, Siitonen SM, et al.. Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. Leukemia. 2019, 33:1324-36. 10.1038\/s41375-018-0307-6","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00577","article-title":"Post-induction measurable residual disease using multicolor flow cytometry is strongly predictive of inferior clinical outcome in the real-life management of childhood T-cell acute lymphoblastic leukemia: a study of 256 patients","volume":"10","author":"Tembhare PR","year":"2020","unstructured":"Tembhare PR, Narula G, Khanka T, et al.. Post-induction measurable residual disease using multicolor flow cytometry is strongly predictive of inferior clinical outcome in the real-life management of childhood T-cell acute lymphoblastic leukemia: a study of 256 patients. Front Oncol. 2020, 10:577. 10.3389\/fonc.2020.00577","journal-title":"Front Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.234","article-title":"Flow cytometry and IG\/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL","volume":"27","author":"Garand R","year":"2013","unstructured":"Garand R, Beldjord K, Cav\u00e9 H, et al.. Flow cytometry and IG\/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia. 2013, 27:370-6. 10.1038\/leu.2012.234","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21831","article-title":"A high-sensitivity 10-color flow cytometric minimal residual disease assay in B-lymphoblastic leukemia\/lymphoma can easily achieve the sensitivity of 2-in-10(6) and is superior to standard minimal residual disease assay: a study of 622 patients","volume":"98","author":"Tembhare PR","year":"2020","unstructured":"Tembhare PR, Subramanian Pg PG, Ghogale S, et al.. A high-sensitivity 10-color flow cytometric minimal residual disease assay in B-lymphoblastic leukemia\/lymphoma can easily achieve the sensitivity of 2-in-10(6) and is superior to standard minimal residual disease assay: a study of 622 patients. Cytometry B Clin Cytom. 2020, 98:57-67. 10.1002\/cyto.b.21831","journal-title":"Cytometry B Clin Cytom"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.5","article-title":"Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia","volume":"22","author":"Flohr T","year":"2008","unstructured":"Flohr T, Schrauder A, Cazzaniga G, et al.. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008, 22:771-82. 10.1038\/leu.2008.5","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141","article-title":"Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry","volume":"152","author":"Thorn I","year":"2011","unstructured":"Thorn I, Forestier E, Botling J, et al.. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol. 2011, 152:743-53. 10.1111\/j.1365-2141","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06033-1","article-title":"Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India","volume":"23","author":"Das N","year":"2022","unstructured":"Das N, Banavali S, Bakhshi S, et al.. Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials. 2022, 23:102. 10.1186\/s13063-022-06033-1","journal-title":"Trials"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21939","article-title":"Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion","volume":"100","author":"Tembhare PR","year":"2021","unstructured":"Tembhare PR, Chatterjee G, Khanka T, et al.. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion. Cytometry B Clin Cytom. 2021, 100:421-33. 10.1002\/cyto.b.21939","journal-title":"Cytometry B Clin Cytom"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.194","article-title":"Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes","volume":"52","author":"Brammer JE","year":"2017","unstructured":"Brammer JE, Saliba RM, Jorgensen JL, et al.. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant. 2017, 52:20-7. 10.1038\/bmt.2016.194","journal-title":"Bone Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.5936","article-title":"Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study","volume":"30","author":"Yeoh AE","year":"2012","unstructured":"Yeoh AE, Ariffin H, Chai EL, et al.. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol. 2012, 30:2384-92. 10.1200\/JCO.2011.40.5936","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181d7ae0d","article-title":"Pattern of relapse in childhood ALL: challenges and lessons from a uniform treatment protocol","volume":"32","author":"Arya LS","year":"2010","unstructured":"Arya LS, Kotikanyadanam SP, Bhargava M, et al.. Pattern of relapse in childhood ALL: challenges and lessons from a uniform treatment protocol. J Pediatr Hematol Oncol. 2010, 32:370-5. 10.1097\/MPH.0b013e3181d7ae0d","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.814130","article-title":"Outcome of treatment with a low cost protocol in adults with T cell acute lymphoblastic leukemia in a tertiary care center in India","volume":"55","author":"Abraham A","year":"2014","unstructured":"Abraham A, George B, Ahmed R, et al.. Outcome of treatment with a low cost protocol in adults with T cell acute lymphoblastic leukemia in a tertiary care center in India. Leuk Lymphoma. 2014, 55:947-9. 10.3109\/10428194.2013.814130","journal-title":"Leuk Lymphoma"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_487_17","article-title":"Clinicoepidemiological profiles, clinical practices, and the impact of holistic care interventions on outcomes of pediatric hematolymphoid malignancies - a 7-year audit of the pediatric hematolymphoid disease management group at Tata Memorial Hospital","volume":"54","author":"Narula G","year":"2017","unstructured":"Narula G, Prasad M, Jatia S, et al.. Clinicoepidemiological profiles, clinical practices, and the impact of holistic care interventions on outcomes of pediatric hematolymphoid malignancies - a 7-year audit of the pediatric hematolymphoid disease management group at Tata Memorial Hospital. Indian J Cancer. 2017, 54:609-15. 10.4103\/ijc.IJC_487_17","journal-title":"Indian J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27716","article-title":"Holistic support coupled with prospective tracking reduces abandonment in childhood cancers: a report from India","volume":"66","author":"Jatia S","year":"2019","unstructured":"Jatia S, Prasad M, Paradkar A, et al.. Holistic support coupled with prospective tracking reduces abandonment in childhood cancers: a report from India. Pediatr Blood Cancer. 2019, 66:e27716. 10.1002\/pbc.27716","journal-title":"Pediatr Blood Cancer"},{"key":"ref20","article-title":"T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434","volume":"124","author":"Wood BL","year":"2014","unstructured":"Wood BL, Winter SS, Dunsmore KP, et al.. T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434. Blood. 2014, 124:1.","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe M","year":"2011","unstructured":"Schrappe M, Valsecchi MG, Bartram CR, et al.. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011, 118:2077-84. 10.1182\/blood-2011-03-338707","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01522.x","article-title":"High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia: biological background and prognostic impact. Results from the NOPHO ALL-92 and ALL-2000 studies","volume":"86","author":"Vaitkevi\u010dien\u0117 G","year":"2011","unstructured":"Vaitkevi\u010dien\u0117 G, Forestier E, Hellebostad M, et al.. High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia: biological background and prognostic impact. Results from the NOPHO ALL-92 and ALL-2000 studies. Eur J Haematol. 2011, 86:38-46. 10.1111\/j.1600-0609.2010.01522.x","journal-title":"Eur J Haematol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00254-9","article-title":"Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis","volume":"3","author":"Conter V","year":"2016","unstructured":"Conter V, Valsecchi MG, Buldini B, et al.. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematol. 2016, 3:80-6. 10.1016\/S2352-3026(15)00254-9","journal-title":"Lancet Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253614-flow-cytometry-based-detection-of-minimalmeasurable-residual-disease-predicts-survival-outcomes-in-pediatrics-adolescents-and-young-adults-with-t-acute-lymphoblastic-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:24:09Z","timestamp":1717575849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253614-flow-cytometry-based-detection-of-minimalmeasurable-residual-disease-predicts-survival-outcomes-in-pediatrics-adolescents-and-young-adults-with-t-acute-lymphoblastic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.61705","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,5]]}}}